Infectious Enteritis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Global Infectious Enteritis Treatment Market Report is segmented By Route of Administration (Oral and Injectables), Drug Type (Antibiotics, Antivirals, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (in USD) for the above segments.

Infectious Enteritis Treatment Market Size

Infectious Enteritis Treatment Market Analysis

The Infectious Enteritis Treatment Market is expected to register a CAGR of 4.9% during the forecast period.

The COVID-19 pandemic had a significant impact on the infectious enteritis market. According to an article published by Clinical Medicine in March 2022, acute gastrointestinal side effects were reported with COVID-19 infection and were estimated to affect around 17% of patients. According to an article published by the Harvard Gazette in November 2021, 60% of patients infected with SARS-CoV-2 also report gastrointestinal symptoms such as nausea, diarrhea, and stomach pain. With an increase in these intestinal enteritis symptoms, the demand for its treatment increase. Therefore, the increasing number of cases of COVID-19 further led to an increased number of cases of infectious enteritis, and thus the market witnessed considerable growth during the pandemic. However, the market is witnessing stabilized growth currently owing to the decrease in COVID-19 cases and the increase in these intestinal enteritis cases, and is expected to project a similar trend over the coming years as per the analysis.

Factors such as the rising population with irritable bowel syndrome (IBS) and diarrhea cases due to infectious enteritis and intensive research and development activities, and Increasing FDA approvals of infectious enteritis treatment drugs are expected to drive the growth of the market over the forecast period. For instance, according to an article published by the Middle East Journal of Digestive Diseases in July 2022, it was estimated that the incidence of IBS is 38.5 per 10,000 persons per year, and the prevalence has been reported to be 10-17% in the general population. Furthermore, according to an article published by BMC Medicine, in March 2022, IBS patients are subtyped based on bowel habit profile into diarrhea (IBS-D), constipation (IBS-C), mixed (IBS-M) or indeterminate, and approximately 10-20% of all cases develop after an episode of acute gastroenteritis. Thus, increase in the population with IBS and diarrhea cases due to infectious enteritis, the demand for its treatment increase, thereby driving the growth of the market over the forecast period.

Additionally, various initiatives taken by the key market players, such as product launches, mergers, acquisitions, and partnerships, are expected to boost the market's growth during the forecast period. For instance, in November 2021, an interdisciplinary panel of infectious disease clinicians and public health experts led by the Center for Disease Dynamics, Economics & Policy (CDDEP) and the Africa CDC released the first edition of the African Antibiotic Treatment Guidelines for Common Bacterial Infections and Syndromes. Such an initiative is expected to drive the growth of the market.

The factors mentioned above are expected to drive the market's growth worldwide. However, several adverse effects associated with the treatment of infectious enteritis and a lack of awareness among people in developing countries are expected to restrain the growth of the studied market over the forecast period.

Infectious Enteritis Treatment Industry Overview

The infectious enteritis treatment market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known, including Actelion Pharmaceuticals, BioGaia, Bristol-Myers Squibb, GlaxoSmithKline plc, Mayne Pharma, Novartis Pharmaceuticals, Pfizer Inc., Teva Pharmaceuticals, among others.

Infectious Enteritis Treatment Market Leaders

  1. Novartis Pharmaceuticals

  2. Teva Pharmaceuticals

  3. Pfizer Inc.

  4. GlaxoSmithKline plc.

  5. Mayne Pharma

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF

Infectious Enteritis Treatment Market News

  • July 2022: Bausch Health Companies Inc. and its gastroenterology business Salix Pharmaceuticals reported that the U.S. District Court of Delaware issued an Oral Order in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. regarding the infringement and validity of certain U.S. Patents protecting the composition and use of XIFAXAN (rifaximin) 550 mg tablets for the treatment of irritable bowel syndrome with diarrhea (IBS-D) and reduction in risk of overt hepatic encephalopathy (HE) recurrence.
  • April 2022: Ardelyx, Inc. received the USFDA for IBSRELA. This is an NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

Infectious Enteritis Treatment Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 The rising population with IBS and diarrhoea cases due to infectious enteritis
    • 4.2.2 Intensive research and development activities and Increasing FDA approvals of infectious enteritis treatment drugs
  • 4.3 Market Restraints
    • 4.3.1 Several adverse effects associated with the treatment of infectious enteritis
    • 4.3.2 Lack of awareness among people in developing countries
  • 4.4 Porter Five Forces
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Route of Administration
    • 5.1.1 Oral
    • 5.1.2 Injectables
  • 5.2 By Drug Type
    • 5.2.1 Antibiotics
    • 5.2.2 Antivirals
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Johnson & Johnson
    • 6.1.2 BioGaia
    • 6.1.3 Bristol-Myers Squibb
    • 6.1.4 GlaxoSmithKline plc
    • 6.1.5 Mayne Pharma
    • 6.1.6 Novartis AG
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Teva Pharmaceuticals
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Infectious Enteritis Treatment Industry Segmentation

As per the scope of this report, enteritis refers to the inflammation of the small intestine. Infectious enteritis is the most common type and includes bacterial and viral enteritis. Eating or drinking contaminated food or water causes bacterial enteritis. Viral enteritis also occurs through eating or drinking contaminated food or water and after contact with someone who has the virus. Viral enteritis usually goes away within a few days. The Infectious Enteritis Treatment Market is Segmented By Route of Administration (Oral and Injectables), Drug Type (Antibiotics, Antivirals, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Route of Administration Oral
Injectables
By Drug Type Antibiotics
Antivirals
Others
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Route of Administration
Oral
Injectables
By Drug Type
Antibiotics
Antivirals
Others
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Infectious Enteritis Treatment Market Research FAQs

What is the current Infectious Enteritis Treatment Market size?

The Infectious Enteritis Treatment Market is projected to register a CAGR of 4.9% during the forecast period (2025-2030)

Who are the key players in Infectious Enteritis Treatment Market?

Novartis Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc. and Mayne Pharma are the major companies operating in the Infectious Enteritis Treatment Market.

Which is the fastest growing region in Infectious Enteritis Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Infectious Enteritis Treatment Market?

In 2025, the North America accounts for the largest market share in Infectious Enteritis Treatment Market.

What years does this Infectious Enteritis Treatment Market cover?

The report covers the Infectious Enteritis Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Infectious Enteritis Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Page last updated on: November 19, 2024

Europe Access Control Hardware Industry Report

Statistics for the 2025 Infectious Enteritis Treatment market share, size and revenue growth rate, created by Mordor Intelligenceâ„¢ Industry Reports. Infectious Enteritis Treatment analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Infectious Enteritis Treatment Market Report Snapshots